Association Between SGLT2 Inhibitor Use and Post-Contrast Acute Kidney Injury in Patients Undergoing Coronary Angiography: A Multicenter Cohort Study

In a multicenter cohort study of patients undergoing coronary angiography, chronic use of SGLT2 inhibitors was identified as an independent protective factor against post-contrast acute kidney injury, significantly reducing the risk even after adjusting for other clinical variables.

The Gist

🏥 The Big Picture: A "Kidney Stress Test"

Imagine your kidneys are like high-performance water filters in a house. They clean your blood constantly. Sometimes, doctors need to take a "picture" of your heart's plumbing (coronary angiography) to see if there are blockages. To make the pipes show up clearly on the X-ray, they inject a special dye called contrast media.

The Problem:
While this dye is great for seeing the heart, it can be a bit toxic to the kidneys. It's like pouring a bucket of thick, heavy mud into a delicate water filter. The mud clogs the tiny tubes, and the filter gets stressed. This can cause a sudden drop in kidney function, known as Post-Contrast Acute Kidney Injury (PC-AKI).

This study asked a simple question: Is there a "shield" we can give patients to protect their kidneys from this muddy water?

---

🛡️ The Hero of the Story: SGLT2 Inhibitors

The researchers looked at a specific group of diabetes medications called SGLT2 inhibitors (think of them as "smart sugar sponges").

• How they work normally: In people with Type 2 diabetes, the kidneys act like a greedy shopkeeper, reabsorbing too much sugar and salt back into the blood. SGLT2 inhibitors tell the kidneys, "Stop! Let that sugar and salt go!" This helps lower blood sugar and blood pressure.
• The Study's Discovery: The researchers found that patients who had been taking these "smart sugar sponges" for at least three months were much less likely to get kidney injury after the dye was injected.

The Analogy:
Imagine the kidney is a busy factory.

• Without the drug: The factory workers are overworked, running back and forth trying to grab every bit of sugar. They are exhausted and overheated (high oxygen demand). When the "muddy water" (dye) hits, the exhausted factory collapses easily.
• With the drug: The drug tells the workers to stop grabbing the sugar. The factory slows down, cools off, and the workers get a break. When the muddy water hits, the factory is fresh, cool, and strong enough to handle the shock without breaking.

---

🔍 What Did They Actually Do?

The researchers looked at 975 patients (about 70% men) who went to the hospital for heart procedures between 2023 and 2024.

1. The Setup: Everyone got the same standard care: lots of IV fluids (like giving the factory a firehose to wash away the mud).
2. The Groups: They split the patients into two groups:
   • Group A: Those taking SGLT2 inhibitors.
   • Group B: Those not taking them.
3. The Result:
   • About 7.3% of all patients developed kidney injury.
   • However, the group taking the SGLT2 inhibitors had a dramatically lower risk. In fact, the study found that taking the drug made you 91% less likely to get kidney injury compared to those who didn't take it.

---

⚠️ Who is Most at Risk?

The study also identified who is most vulnerable to this "kidney shock." Think of these as the "Red Flags":

• Age: Being over 65.5 years old.
• Diabetes: Having Type 2 diabetes.
• High Uric Acid: Having high levels of uric acid (like having too much rust in the pipes).

If you have these red flags, your kidneys are already working harder, so the dye hits them even harder.

---

💡 Why Does This Matter?

For a long time, the only way to protect kidneys from this dye was to give them lots of water (IV fluids). It's like trying to wash mud out of a filter with a garden hose. It helps, but it's not perfect.

This study suggests that SGLT2 inhibitors act like a pre-strengthened shield. By taking these drugs before the procedure, the kidneys become more resilient. They consume less oxygen and handle the stress of the dye much better.

🏁 The Bottom Line

This isn't just about lowering blood sugar anymore. For patients with diabetes needing heart scans, taking SGLT2 inhibitors might be a secret weapon to save their kidneys.

• The Old Way: Give water, hope for the best.
• The New Hope: Give water plus SGLT2 inhibitors to actively protect the kidney's "factory" from the shock of the dye.

Note: While this is a very promising study, the authors remind us that we need more randomized trials (like a controlled experiment) to say for sure that the drug causes the protection, rather than just being associated with it. But the results are exciting enough to make doctors think twice about how they prepare high-risk patients for heart procedures.

Technical Summary

1. Problem Statement

Post-Contrast Acute Kidney Injury (PC-AKI) is a significant clinical complication, particularly in patients with Type 2 Diabetes Mellitus (T2DM) and pre-existing renal vulnerabilities undergoing coronary angiography or percutaneous coronary intervention (PCI).

• Pathophysiology: PC-AKI is driven by renal ischemia (due to contrast-induced vasoconstriction and medullary hypoxia) and direct tubular toxicity.
• Current Limitations: While intravenous hydration is the standard preventive strategy, effective pharmacological interventions remain limited. High-risk populations (T2DM, CKD) still experience PC-AKI rates ranging from 10% to 26% despite hydration.
• Research Gap: There is a need to identify novel protective agents. Sodium–glucose co-transporter-2 (SGLT2) inhibitors are known for cardiorenal benefits, but their specific role in mitigating acute contrast-induced injury in a real-world clinical setting requires further investigation.

2. Methodology

Study Design:

• Type: Multicenter, observational cohort study.
• Setting: Three tertiary care centers in Türkiye.
• Timeline: June 2023 to June 2024.
• Population: 975 patients (aged 18–75) undergoing coronary angiography and/or PCI with iodinated contrast.
• Inclusion/Exclusion:
  • Included: Patients with baseline eGFR 25–115 mL/min/1.73 m² who received standardized IV hydration (0.9% saline at 1 mL/kg/h for 6h pre- and 12h post-procedure).
  • Excluded: Baseline AKI, prior prophylactic pharmacologic interventions (e.g., N-acetylcysteine), contrast volume >100 mL, non-iso-osmolar contrast, or inability to tolerate aggressive hydration.

Exposure Definition:

• SGLT2 Inhibitor Users: Patients using SGLT2 inhibitors for ≥3 months prior to the procedure.
• Non-Users: Patients with T2DM not using SGLT2 inhibitors or who discontinued >3 months prior.

Outcome Definition:

• Primary Outcome: PC-AKI, defined as a ≥25% increase in serum creatinine from baseline OR an absolute increase of ≥0.5 mg/dL within 48–72 hours post-contrast.

Statistical Analysis:

• Tools: SPSS v24.0 and Excel.
• Methods:
  • ROC curve analysis to determine optimal cut-off values for continuous variables (age, urea, creatinine, eGFR, etc.).
  • Univariate logistic regression to identify potential risk factors.
  • Multivariate logistic regression (Forward Stepwise Likelihood Ratio) to identify independent predictors.
  • Post-hoc power analysis confirmed >80% power to detect the observed association.

3. Key Contributions

• First Real-World Evidence: This study provides multicenter, real-world data suggesting that chronic SGLT2 inhibitor use is associated with a significantly reduced risk of PC-AKI in patients undergoing coronary procedures, even after adjusting for confounders.
• Risk Stratification: The study established specific cut-off values for predicting PC-AKI (e.g., Age ≥65.5, Uric Acid >6.75 mg/dL, eGFR <81.5) using ROC analysis.
• Mechanistic Insight: It reinforces the hypothesis that SGLT2 inhibitors offer acute renoprotection beyond long-term chronic kidney disease (CKD) management, likely via hemodynamic and metabolic mechanisms.

4. Key Results

Demographics & Incidence:

• Total Cohort: 975 patients (Mean age 59.2 ± 11.7; 70.8% male).
• Comorbidities: 39% had T2DM; 16.9% were chronic SGLT2 inhibitor users.
• PC-AKI Incidence: 7.3% (71 patients). Only 0.7% required renal replacement therapy (RRT).

Predictive Factors (Univariate Analysis):

• Risk Factors (Increased Risk): Age ≥65.5 (OR 4.61), Diabetes (OR 2.01), Hypertension (OR 2.32), Heart Failure (OR 1.89), Diuretic use (OR 2.38), Urea >46.5 mg/dL (OR 4.97), Creatinine >0.94 mg/dL (OR 3.65), Uric Acid >6.75 mg/dL (OR 4.82).
• Protective Factors: eGFR >81.5 (OR 0.15), Albumin >3.92 g/dL (OR 0.22), Sodium >137.5 mmol/L (OR 0.44), SGLT2 Inhibitor Use (OR 0.28).

Multivariate Analysis (Independent Predictors):
After adjusting for confounders, the following remained significant:

• Independent Risk Factors:
  • Age ≥65.5 years (OR 4.53; 95% CI 1.98–10.37).
  • Diabetes Mellitus (OR 2.49; 95% CI 1.13–5.46).
  • Uric Acid >6.75 mg/dL (OR 2.34; 95% CI 1.08–5.08).
• Independent Protective Factors:
  • SGLT2 Inhibitor Use (OR 0.09; 95% CI 0.02–0.42; p=0.002). This indicates a ~91% reduction in the odds of developing PC-AKI for users compared to non-users.
  • eGFR >81.5 mL/min/1.73 m² (OR 0.38).
  • Sodium >137.5 mmol/L (OR 0.36).

5. Significance and Conclusion

Clinical Implications:
The study suggests that SGLT2 inhibitors may serve as a potent prophylactic agent against PC-AKI in high-risk diabetic patients. The protective effect is likely multifactorial:

1. Hemodynamic: Restoration of tubuloglomerular feedback reduces intraglomerular pressure and hyperfiltration.
2. Metabolic/Oxygenation: By inhibiting sodium reabsorption, SGLT2 inhibitors reduce the metabolic workload (oxygen consumption) of the proximal tubule, thereby improving medullary oxygenation and resilience against contrast-induced hypoxia.
3. Anti-inflammatory: Potential attenuation of hypoxia-induced inflammatory pathways (e.g., HIF-1α/NF-κB).

Limitations:

• Observational nature (cannot definitively prove causality; potential unmeasured confounders).
• Lack of data on specific SGLT2 inhibitor types/doses.
• Short-term follow-up (only acute phase).

Conclusion:
Beyond their established long-term cardiorenal benefits, chronic SGLT2 inhibitor use is strongly associated with a reduced risk of acute kidney injury following contrast exposure. The authors recommend considering SGLT2 inhibitors as part of a comprehensive renoprotective strategy for high-risk patients undergoing coronary angiography, pending confirmation via prospective randomized controlled trials.